While Abbott Laboratories has overperformed by 0.32%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ABT rose by 2.35%, with highs and lows ranging from $121.64 to $99.71, whereas the simple moving average jumped by 2.59% in the last 200 days.
On October 08, 2024, Oppenheimer started tracking Abbott Laboratories (NYSE: ABT) recommending Outperform. A report published by Piper Sandler on September 19, 2024, Initiated its previous ‘Overweight’ rating for ABT. Goldman Initiated an Buy rating on May 30, 2024, and assigned a price target of $121. Wolfe Research July 21, 2023d its ‘Underperform’ rating to ‘Peer Perform’ for ABT, as published in its report on July 21, 2023. Morgan Stanley’s report from May 30, 2023 suggests a price prediction of $112 for ABT shares, giving the stock a ‘Equal-Weight’ rating. Wolfe Research also rated the stock as ‘Underperform’.
Analysis of Abbott Laboratories (ABT)
A return on investment can be expected regardless of ABT’s performance over the next quarter with the dividend set at $2.20 per share. Further, the quarter-over-quarter increase in sales is 4.85%, showing a positive trend in the upcoming months.
To gain a thorough understanding of Abbott Laboratories’s future performance, several well-rounded types of analysis and research techniques can be used, with equity being among the most crucial. The goal here is to ensure that your current return on equity of 14.87% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 1.14, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
It is also very valuable to look at average volume as an indicator of volatility for a stock, and ABT is recording an average volume of 5.05M. On a monthly basis, the volatility of the stock is set at 1.47%, whereas on a weekly basis, it is put at 1.13%, with a gain of 0.53% over the past seven days. Furthermore, long-term investors anticipate a median target price of $132.18, showing growth from the present price of $113.40, which can serve as yet another indication of whether ABT is worth investing in or should be passed over.
How Do You Analyze Abbott Laboratories Shares?
A leading company in the Medical Devices sector, Abbott Laboratories (ABT) is based in the USA. When comparing Abbott Laboratories shares with other companies under Healthcare, the P/E value is an influential factor to note. This is because it represents an indication of the future growth of the company in terms of investors’ expectations. Ultimately, the value of the latter should demonstrate steady, rapid growth, which is an accurate measure of the company’s progress. In addition to the value of 34.49, there is a growth in quarterly earnings of 14.65%.
The number of employees owning shares of the company should also be considered in addition to the fundamentals. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 0.66%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 76.58% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
ABT shares are owned by institutional investors to the tune of 76.58% at present.
